ARROWHEAD PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $9.2B
- as of Sep 30, 2026
- Shares Outstanding
- 141.3M
- Free Float
- 91.4%
Income Statement
- Revenue
- $829.4M
- Operating Income
- $98.3M
- Net Income
- -$1.6M
- EBITDA
- $120.5M
- Revenue Growth, 3Y
- 50.5%
- FCF Margin, 3Y Avg
- -5712.2%
- FCF Margin, Worst Year
- -17018.3%
Cash Flow
- Free Cash Flow
- $156.9M
- FCF Yield
- 1.7%
- Owner FCF Yield
- 1.0%
Returns & Capital
- SBC, 3Y Avg
- $71.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $829.4M | $156.9M | 18.9% |
| FY2024 | $3.6M | -$604.3M | -17018.3% |
| FY2023 | $240.7M | -$330.6M | -137.3% |
| FY2022 | $243.2M | -$188.9M | -77.7% |
| FY2021 | $138.3M | $147.7M | 106.8% |
Annual filing data through FY ended September 30, 2025; shares and float as of October 23, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back